NCT01876771View on ClinicalTrials.gov

A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

PHASE2RecruitingINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

April 29, 2014

Primary Completion Date

December 31, 2042

Study Completion Date

December 31, 2042

Conditions

Carcinoma, Neuroendocrine

Interventions

DRUG

[177]Lu-DOTA-TATE

Peptide receptor radionuclide therapy (PPRT)

Trial Locations (1)

T6G 1Z2

RECRUITING

Cross Cancer Institute, Edmonton

All Listed Sponsors

lead

AHS Cancer Control Alberta

OTHER

NCT01876771 - A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours | Biotech Hunter | Biotech Hunter